LINDSEY SEIPP: Open Payments
NPI 1629664388 · LEWISTON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 47 payments from 15 companies in 2025. Trend: 2023 $535 · 2024 $1,038 · 2025 $862
Food & beverage: $862
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $228 |
| AstraZeneca Pharmaceuticals LP | 5 | $181 |
| PFIZER INC. | 14 | $159 |
| GlaxoSmithKline, LLC. | 3 | $75 |
| Lundbeck LLC | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Novo Nordisk Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
Products named: NURTEC ODT, FARXIGA, UBRELVY, QULIPTA, TRELEGY ELLIPTA, REXULTI, AIRSUPRA, ELIQUIS.
Industry payments across ID — which companies pay providers there.
